TDMS Study 89006-02 Pathology Tables
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
CORE STUDY
Facility: Southern Research Institute
Chemical CAS #: 30516-871
Lock Date: 11/01/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 7 6 5 9
Moribund Sacrifice 7 8 11 12
Dosing Accident 3 2 2 4
Accidently Killed 2
Survivors
Terminal Sacrifice 33 32 32 24
Missing 1
Animals Examined Microscopically 50 50 50 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (48) (47) (49) (48)
Fibrosarcoma, Metastatic, Uterus 1 (2%)
Intestine Large, Colon (50) (48) (50) (49)
Leiomyoma 1 (2%)
Intestine Small, Jejunum (50) (49) (49) (49)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (49) (49) (46) (47)
Liver (50) (50) (50) (49)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node,
Mesenteric 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 12 (24%) 2 (4%) 3 (6%) 6 (12%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (4%) 2 (4%) 4 (8%)
Hepatocellular Adenoma 8 (16%) 14 (28%) 11 (22%) 11 (22%)
Hepatocellular Adenoma, Multiple 3 (6%) 3 (6%) 3 (6%) 3 (6%)
Histiocytic Sarcoma 2 (4%) 3 (6%) 1 (2%)
Mesentery (10) (11) (9) (6)
Carcinoma, Metastatic, Uterus 1 (11%)
Fibrosarcoma 1 (11%)
Hemangioma 1 (10%)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (17%)
Pancreas (50) (50) (50) (49)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (49) (49) (48)
Stomach, Forestomach (50) (50) (50) (49)
Page 2
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Carcinoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (50) (49)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (50) (50) (49)
Heart (50) (50) (50) (49)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (49) (49) (49) (48)
Pheochromocytoma Malignant 2 (4%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (50) (49)
Adenoma 1 (2%)
Pituitary Gland (50) (47) (48) (47)
Pars Distalis, Adenoma 7 (14%) 3 (6%) 4 (8%) 5 (11%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%) 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Bilateral, Follicular Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (49) (49) (49)
Cystadenoma 4 (8%) 2 (4%)
Fibrosarcoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%)
Luteoma 1 (2%)
Uterus (50) (50) (50) (49)
Page 3
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Fibrosarcoma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 3 (6%) 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Carcinoma 1 (2%) 1 (2%)
Endometrium, Polyp Stromal 4 (8%) 3 (6%) 2 (4%)
Endometrium, Sarcoma Stromal 1 (2%)
Vagina (49) (44) (48) (48)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma 5 (10%) 6 (13%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Lymph Node (4) (8) (10) (10)
Histiocytic Sarcoma 1 (13%)
Iliac, Histiocytic Sarcoma 1 (13%) 1 (10%)
Inguinal, Histiocytic Sarcoma 1 (13%)
Inguinal, Squamous Cell Carcinoma,
Metastatic, Vagina 1 (10%)
Mediastinal, Fibrosarcoma, Metastatic,
Mesentery 1 (10%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Lymph Node, Mesenteric 1 (10%)
Mediastinal, Histiocytic Sarcoma 1 (13%)
Renal, Histiocytic Sarcoma 1 (13%) 1 (10%)
Lymph Node, Mandibular (49) (45) (46) (48)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (50) (47) (49) (49)
Fibrous Histiocytoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Spleen (50) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Thymus (47) (46) (46) (45)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (49) (50) (49)
Carcinoma 1 (2%)
Skin (49) (50) (50) (49)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%)
Page 4
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 4 (8%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (50) (50) (49)
Osteosarcoma 1 (2%) 1 (2%)
Skeletal Muscle (50) (50) (50) (49)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Uterus 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (49)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Spinal Cord (2) (2) (7) (3)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (49)
Alveolar/Bronchiolar Adenoma 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (1)
Adenoma 2 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (49)
Histiocytic Sarcoma 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%)
Urinary Bladder (50) (50) (50) (49)
Page 5
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(49)
Histiocytic Sarcoma 3 (6%) 3 (6%) 1 (2%)
Lymphoma Malignant 13 (26%) 8 (16%) 12 (24%) 11 (22%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 39 38 36
Total Primary Neoplasms 60 58 61 62
Total Animals with Benign Neoplasms 23 25 23 20
Total Benign Neoplasms 28 33 26 27
Total Animals with Malignant Neoplasms 23 23 28 28
Total Malignant Neoplasms 32 25 35 35
Total Animals with Metastatic Neoplasms 2 1 5 1
Total Metastatic Neoplasm 2 1 19 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 13 14 5 9
Natural Death 1 7 4 6
Dosing Accident 2 2
Accidently Killed 1
Survivors
Terminal Sacrifice 36 27 38 35
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Intestine Small, Jejunum (50) (50) (48) (50)
Carcinoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node,
Mesenteric 1 (2%)
Intestine Small, Ileum (50) (48) (49) (50)
Liver (50) (50) (50) (50)
Carcinoid Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Cholangiocarcinoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node,
Mesenteric 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 2 (4%) 3 (6%) 3 (6%) 3 (6%)
Hepatoblastoma 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma 12 (24%) 13 (26%) 15 (30%) 9 (18%)
Hepatocellular Carcinoma, Multiple 1 (2%) 7 (14%) 2 (4%) 5 (10%)
Hepatocellular Adenoma 10 (20%) 12 (24%) 14 (28%) 14 (28%)
Hepatocellular Adenoma, Multiple 6 (12%) 4 (8%) 5 (10%) 4 (8%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Ito Cell Tumor Benign 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Mesentery (1) (2) (1)
Cholangiocarcinoma, Metastatic, Liver 1 (50%)
Sarcoma 1 (50%)
Pancreas (50) (50) (50) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Page 8
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (4%)
Stomach, Glandular (50) (50) (50) (50)
Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoid Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Bilateral, Capsule, Adenoma 1 (2%)
Capsule, Adenoma 2 (4%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%)
Pituitary Gland (48) (43) (48) (47)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Pars Intermedia, Carcinoma 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 3 (6%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (48) (48) (50) (50)
Carcinoma 1 (2%)
Prostate (50) (50) (48) (50)
Testes (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (5) (8) (5) (5)
Iliac, Histiocytic Sarcoma 1 (20%)
Inguinal, Histiocytic Sarcoma 1 (20%)
Pancreatic, Fibrous Histiocytoma, Metastatic,
Lymph Node, Mesenteric 1 (13%)
Pancreatic, Sarcoma, Metastatic, Skeletal
Muscle 1 (13%)
Renal, Fibrous Histiocytoma, Metastatic,
Lymph Node, Mesenteric 1 (20%)
Renal, Histiocytic Sarcoma 1 (20%) 1 (13%)
Lymph Node, Mandibular (46) (47) (49) (46)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Lymph Node, Mesenteric (50) (48) (50) (47)
Fibrous Histiocytoma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Spleen (50) (49) (49) (50)
Fibrous Histiocytoma, Metastatic, Lymph Node,
Mesenteric 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (45) (40) (42) (43)
Fibrosarcoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node,
Mesenteric 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (3%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Skeletal Muscle (50) (50) (50) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 7 (14%) 3 (6%) 7 (14%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 2 (4%) 6 (12%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 1 (2%)
Carcinoid Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node,
Mesenteric 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 3 (6%) 2 (4%) 3 (6%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (3) (1) (5)
Adenoma 3 (100%) 3 (100%) 1 (100%) 2 (40%)
Carcinoma 2 (40%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 2 (4%)
Lymphoma Malignant 7 (14%) 8 (16%) 5 (10%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 89006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 08/21/96
Route: GAVAGE Time: 09:09:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 500 U 500 U 500 U
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 41 42 47
Total Primary Neoplasms 72 72 69 75
Total Animals with Benign Neoplasms 26 20 26 30
Total Benign Neoplasms 36 25 33 36
Total Animals with Malignant Neoplasms 30 32 29 33
Total Malignant Neoplasms 36 47 36 39
Total Animals with Metastatic Neoplasms 4 8 2 5
Total Metastatic Neoplasm 4 23 2 13
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------